{"id":592225,"date":"2022-03-21T20:12:01","date_gmt":"2022-03-21T20:12:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=592225"},"modified":"2022-03-21T20:12:01","modified_gmt":"2022-03-21T20:12:01","slug":"focal-segmental-glomerulosclerosis-fsgs-pipeline-emerging-therapies-clinical-trials-and-treatment-outlook-key-players-retrophin-aurinia-dimerix-complexa-bristolmyers-squibb-and-astellas","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/focal-segmental-glomerulosclerosis-fsgs-pipeline-emerging-therapies-clinical-trials-and-treatment-outlook-key-players-retrophin-aurinia-dimerix-complexa-bristolmyers-squibb-and-astellas_592225.html","title":{"rendered":"Focal Segmental Glomerulosclerosis (FSGS) Pipeline: Emerging Therapies, Clinical Trials, and Treatment Outlook | Key Players &#8211; Retrophin, Aurinia, Dimerix, Complexa, Bristol-Myers Squibb, and Astellas"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Focal Segmental Glomerulosclerosis (FSGS) Pipeline: Emerging Therapies, Clinical Trials, and Treatment Outlook | Key Players - Retrophin, Aurinia, Dimerix, Complexa, Bristol-Myers Squibb, and Astellas\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Focal Segmental Glomerulosclerosis (FSGS) Pipeline: Emerging Therapies, Clinical Trials, and Treatment Outlook | Key Players - Retrophin, Aurinia, Dimerix, Complexa, Bristol-Myers Squibb, and Astellas\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">\u201cFocal Segmental Glomerulosclerosis Pipeline Insight, 2022&#8243; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Focal Segmental Glomerulosclerosis Market.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Focal Segmental Glomerulosclerosis Pipeline<\/strong> report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report also covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Focal Segmental Glomerulosclerosis Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/66e5b976e370355129ab69ddc483cafb.jpg\" alt=\"Focal Segmental Glomerulosclerosis Pipeline Analysis\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Focal Segmental Glomerulosclerosis Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights about companies that are developing therapies for the <strong>treatment of Focal Segmental Glomerulosclerosis<\/strong> with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Focal Segmental Glomerulosclerosis Treatment.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Focal Segmental Glomerulosclerosis key companies<\/strong> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Focal Segmental Glomerulosclerosis Drugs<\/strong> under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the <strong>Focal Segmental Glomerulosclerosis market<\/strong>.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample Pages @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Focal Segmental Glomerulosclerosis Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>The available therapeutics treatment options in the Focal Segmental Glomerulosclerosis (FSGS) landscape aims to reduce complications and protect from further kidney damage. Few companies are performing clinical trials to develop cell therapies and receptor modulators for the treatment of FSGS.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key companies in the Focal Segmental Glomerulosclerosis (FSGS) Market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Retrophin<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Aurinia Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Dimerix<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Complexa<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bristol-Myers Squibb<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Astellas Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pfizer<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Focal Segmental Glomerulosclerosis (FSGS) Therapies covered in the report include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Sparsentan<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Voclosporin<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">DMX-200<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">CXA-10<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Abatacept<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bleselumab<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">PF-06730512<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many more.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for Sample Pages @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Focal Segmental Glomerulosclerosis&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Focal Segmental Glomerulosclerosis Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Focal Segmental Glomerulosclerosis &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Focal Segmental Glomerulosclerosis Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Focal Segmental Glomerulosclerosis Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Focal Segmental Glomerulosclerosis Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Focal Segmental Glomerulosclerosis Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Focal Segmental Glomerulosclerosis Key Companies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Focal Segmental Glomerulosclerosis Key Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Focal Segmental Glomerulosclerosis Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Focal Segmental Glomerulosclerosis Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Focal Segmental Glomerulosclerosis Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Visit to get the sample report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Latest Reports By DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-thrombocytopenic-purpura-market\">Idiopathic Thrombocytopenic Purpura Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s &ldquo;<strong>Idiopathic Thrombocytopenic Purpura Market<\/strong>&rdquo; report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, Idiopathic Thrombocytopenic Purpura market size, share, trends in the 7MM as well emerging therapies and the key companies operating in the domain.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=focal-segmental-glomerulosclerosis-fsgs-pipeline-emerging-therapies-clinical-trials-and-treatment-outlook-key-players-retrophin-aurinia-dimerix-complexa-bristolmyers-squibb-and-astellas\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=focal-segmental-glomerulosclerosis-fsgs-pipeline-emerging-therapies-clinical-trials-and-treatment-outlook-key-players-retrophin-aurinia-dimerix-complexa-bristolmyers-squibb-and-astellas\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP \u201cFocal Segmental Glomerulosclerosis Pipeline Insight, 2022&#8243; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Focal Segmental Glomerulosclerosis Market. The Focal Segmental Glomerulosclerosis Pipeline report embraces in-depth commercial and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/focal-segmental-glomerulosclerosis-fsgs-pipeline-emerging-therapies-clinical-trials-and-treatment-outlook-key-players-retrophin-aurinia-dimerix-complexa-bristolmyers-squibb-and-astellas_592225.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-592225","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/592225","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=592225"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/592225\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=592225"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=592225"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=592225"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}